A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease
A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease
开始日期2022-02-21
申办/合作机构-
100 项与 α2A-AR x 5-HT2C receptor x 5-HT2A receptor x 5-HT7 receptor 相关的临床结果
登录后查看更多信息
100 项与 α2A-AR x 5-HT2C receptor x 5-HT2A receptor x 5-HT7 receptor 相关的转化医学
登录后查看更多信息
0 项与 α2A-AR x 5-HT2C receptor x 5-HT2A receptor x 5-HT7 receptor 相关的专利(医药)